1.HEPATOLOGY DIGEST: Right, so through these integrative efforts we might be able to control the progression of liver cancer, right?
《国际肝病》：那么是不是通过这些综合治疗手段我们就可能控制肝癌的进展？
2.Hepatology Digest: Thank you both. It was a pleasure and I hope to see you next year.
国际肝病：感谢二位，非常高兴，希望明年再次见面。
3.Hepatology Digest: The last thing I would like to ask you about is sorafenib .
国际肝病：最后我想问的是索拉非尼。
4.Hepatology Digest: how do you think the clinical practice of proteinase inhibitors ? Will the side effects affect its clinical use?
《国际肝病》：您怎样看待蛋白酶抑制剂在临床上的应用以及这些药物的副作用？
5.Hepatology Digest: The liver is known as an immunologically privileged organ in solid organ transplants.
《国际肝病》：在实体器官移植中，肝脏被称为免疫特惠器官。
6.Hepatology Digest: From your experience, RFA is an efficient treatment for HCC. What are the indications and contraindications for RFA?
《国际肝病》：从您的经验来看，RFA是一种治疗肝细胞癌的有效方法。那么RFA的适应证和禁忌证有哪些？
7.Hepatology Digest: The reason I ask is that there is a bit of a mixed message here. Red wine is promoted as a good anti-oxidant for example.
《国际肝病》：之所以我这么问是有一点潜藏在这里，例如红酒被作为一种良好的抗氧化。
8.Hepatology Digest: Professor Jia, do you know of any similar compounds that are being researched in China?
《国际肝病》：贾教授，就您所知，是否有其他类似化合物在中国正在被研究呢？
9.Hepatology Digest: It seems that most people today don't recommend switching at this point and it is more of an add-on strategy.
肝病文摘：看来，大多数人今天不建议交换在这一点上，它更是一个附加的战略。
10.Hepatology Digest: The two approved DAA drugs, telaprevir and boceprevir, were thought of the first generation protease inhibitors.
《国际肝病》：已批准的两种DAA，telaprevir和boceprevir，是第一代蛋白酶抑制剂。